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Abstract
Background: Tumour stromal macrophages differentiate to tumour-associated macrophages (TAMs) with characteristics
of immunosuppressive M2-type macrophages, having a central role in promoting tumour vascularisation, cancer
cell dissemination and in suppressing anti-cancer immune responses. Bisphosphonates (BPs) are a group of drugs
commonly used as anti-resorptive agents. Further, nitrogen containing BPs like Zoledronate (ZOL), are known to
cause unspecific inflammatory reactions hence the hypothesis that its use could modulate TAMs polarization toward a
more inflammatory phenotype.
Methods: We studied the in vitro polarization of J774 murine macrophages upon culture in 4T1 breast cancer cell-
conditioned medium (4T1CM) and stimulation with LPS and free and liposome-encapsulated bisphosphonates.
Results: In this system, breast cancer soluble factors reduced the pro-inflammatory activation of macrophages but
increased the secretion of matrix metalloproteinases (MMPs). In the presence of 4T1CM, a non-cytotoxic dose of
liposome-encapsulated ZOL (ZOL-LIP) enhanced the expression of iNOS and TNF-α, markers of M1 activation, but did
not diminish the expression of M2-type markers. In contrast, clodronate treatment either as a free drug (CLO) or
liposome-encapsulated (CLO-LIP) decreased the expression of the M1-type markers and was highly cytotoxic to the
macrophages.
Conclusions: Breast cancer cells soluble factors modulate macrophages toward M2 activation state. Bisphosphonates
may be applied to counteract this modulation. We propose that ZOL-LIP may be suitable for favouring cytotoxic
immune responses by TAMs in breast cancer, whereas CLO-LIP may be appropriate for TAM depletion.
Keywords: Breast Cancer, Tumour-associated Macrophages, Bisphosphonates, Clodronate, Zoledronate, Cytokines,
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Background
Macrophages exhibit a wide spectrum of activation phe-
notypes with two extremes (similar to the Th1/Th2 para-
digm of T cells), the classically activated M1 macrophages
and the alternatively activated M2 macrophages [1]. M1
macrophages protect against infections and tumour cell
proliferation, phagocytose invading organisms, release ni-
tric oxide (NO) or reactive oxygen species (ROS), present
antigens to T cells and secrete immunomodulatory and
pro-inflammatory cytokines [1,2]. M1 macrophages se-
crete low levels of IL-10 and high levels of IL-12, IL-6, and
TNF-α and possess antitumour activity [2-6]. M2 macro-
phages scavenge tissue debris, display poor antigen pre-
senting capabilities, promote angiogenesis and suppress T
cell and natural killer cell proliferation and activity [7,8].
They produce high levels of IL-10, TGF-β, CCL-1, and
CCL-22 and low levels of IL-12 and promote tumour
growth and metastasis [3].
Tumour tissues are chronically inflamed and are cap-
able of reprogramming the infiltrating immune cells to
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promote tumour progression [9,10]. The phenotype of
most of the human tumour-associated macrophages
(TAMs) resembles the M2 phenotype. These TAMs have
been proven to support tumour growth, invasion, migra-
tion and metastasis [11].
Bisphosphonates (BPs) a class of anti-resorptive drugs
are taken up by phagocytosing cells [12]. Based on their
structure BPs can be divided into two categories, non-
nitrogen-containing bisphosphonates (non N-BPs) and
nitrogen-containing bisphosphonates (N-BPs). Both types
have high affinity for bone [13].
Non N-BPs, such as clodronate (CLO), have a struc-
ture that closely resembles PPi and are incorporated into
methylene-containing ATP analogues (AppCp-type me-
tabolites). These ATP analogues are resistant to metab-
olism and inhibit cellular proliferation. They induce
apoptosis by inhibiting the mitochondrial adenine nu-
cleotide translocase (ANT) [13,14]. N-BPs, such as zole-
dronate (ZOL), inhibit farnesyl diphosphate synthase
(FDPS), an enzyme of the mevalonate pathway. This
leads to accumulation of unprenylated proteins and
mevalonate pathway intermediates, such as isopentenyl
pyrophosphate (IPP). IPP is further converted to tripho-
sphoric acid 1-adenosin-5′-yl-ester3-(3-methylbut-3-enyl)
ester (ApppI), possibly by aminoacyl-tRNA synthases
[13,15]. ApppI also inhibits ANT thus inducing apoptosis.
IPP is known to be an antigen recognised by γδ-T cells
and such recognition, together with effects on monocytic
lineage cells, contributes to the acute phase reaction, a
common side effect of N-BPs [13,16].
N-BPs have been shown to inhibit macrophage prolif-
eration, migration and invasion [17]. It has been demon-
strated that N-BPs decrease MMP-9 secretion by breast
tumour-bearing mice (the FVB x BALB-neuT model),
thereby decreasing tumour infiltration by macrophages
[18]. N-BPs have also been reported to reverse the polarity
of TAMs from M2 to M1 in BALB-neuT and BALB-
neuT/IFN-γ knockout murine models of mammary car-
cinoma [19]. TAMs are therefore highly suitable N-BPs
target cells as long as their affinity for bone can be
overcome in vivo. Liposomes have been proven to be
effective carriers of BPs to macrophages enhancing BPs
potency by factors of 20-1,000 [20].
In this study, we characterised for the first time the ef-
fects of soluble factors secreted by breast cancer cells on
macrophage activation in the presence or absence of free
and liposome-encapsulated BPs.
Methods
Liposome encapsulation of Zoledronate and Clodronate
Stock solutions of ZOL and CLO were encapsulated in
negatively charged unilamellar liposomes by reverse-
phase evaporation [20] using distearoylphosphatidylglycerol
(DSPG) and cholesterol (2:1 ratio). The concentrations of
ZOL and CLO were measured spectrophotometrically
[20]. The lipid content of the liposomes was determined
by a phosphorous assay [21] and the size distribution was
analysed using the Nicomp 380XLS Zeta Potential/Particle
Sizer, the mean diameter was under 300 nm. The concen-
tration of the liposome-encapsulated compounds(X-LIP)
was 1 mM ZOL-LIP and 10 mM CLO-LIP. The molar
drug:phospholipid ratio was 1.5 for CLO-LIP and 0.5 for
ZOL-LIP.
Cell culture
With the exception of J774 cells, which were cultured in
DMEM (Sigma), all other cell lines were cultured in
RPMI-1640 (Sigma) supplemented with 10% FBS (Gibco)
and 100 IU/ml penicillin and streptomycin (Gibco) at
37°C in a 5% CO2 atmosphere. The murine 4T1 breast
cancer cell line and 3T3 fibroblast cell line were from the
American Type Culture Collection. The J774 murine
macrophage cell line was from the European Collection of
Cell Cultures.
For studies of IPP, ApppI and AppCCl2p production
and western blot analysis, cells were seeded into 6-well
plates at a density of 5 × 105 cells per well. Treatments
were performed for 24 h, using 500 μM CLO, 10 μM
ZOL, 50 μM CLO-LIP and 1 μM ZOL-LIP diluted in
PBS.
Cell viability, growth inhibition and cytotoxicity
To assess growth inhibition and cytotoxicity, J774 cells
were plated at a density of 2.5 × 103 and 1 × 104 cells
per well, respectively, in 96-well plates. Treatments were
done with drug solutions from half-logarithmic dilution
series, for 72 h. Cell viability was evaluated using the
MTT assay as previously described [22].
Studies assessing macrophage activation
Conditioned media (CM) from three independent 4T1
and 3T3 murine cell line batches were collected 72 h
after the cells reached confluence. The batches were
cleared by centrifugation and used as 50% supplements
of J774 culture medium together with 10% FBS. After
72 h of culture with CM, J774 cells were stimulated for
24 h with 10 ng/mL LPS (E. coli serotype 026:B6, Sigma).
LPS is a bacterial cell wall component known to act as a
macrophage activator [23]. BPs were added 24 h before
LPS stimulation (concentrations, see above). Cells were
harvested for RNA extraction, and supernatants were
collected for cytokine quantitation and Griess assay. Par-
allel FBS-free, LPS-treated supernatants were collected
for zymography, and cells were harvested for acetonitrile
(ACN)/water extraction and IPP, ApppI and AppCCl2p
determination.
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HPLC-MS conditions for IPP, ApppI and AppCCl2p
quantitation
IPP, ApppI and AppCCl2p were determined in dried
ACN/water cell extracts by HPLC-ESI-MS as previously
described [17,24]. Quantification of the molecules was
performed using LCquan 2.0 software (Thermo Finnigan)
using authentic standard curves with AppCp (Sigma) as
an internal standard.
SDS-PAGE and Western blot analysis
Whole cell lysates were prepared for SDS-PAGE and west-
ern blot analysis of FDPS (rabbit polyclonal anti-FDPS,
Abgent), Rap1A (goat polyclonal anti-Rap1A, Santa Cruz
Biotechnology) and β-actin (mouse monoclonal anti-β-
actin, Santa Cruz Biotechnology) as previously described
[25]. An enhanced chemiluminescence (ECL) system was
used for detection, and Image Quant RT ECL (GE Health-
care) was used for blot scanning.
Cytokine quantification and Griess Assay
Interferon γ (IFN-γ), Interleukin 4 (IL-4), IL-10, IL-12
(p70), IL-6, Macrophage Colony-Stimulating Factor (M-
CSF), Monocyte Chemotactic Protein-1 (MCP-1), Tumour
Necrosis Factor (TNF-α) and Vascular Endothelial Growth
Factor (VEGF) were measured using a Murine Multiplex
ELISA kit (Milliplex MAP-kit, Millipore, MCYTOMAG-
70 K-9P) and analysed on a Luminex 200™ System. NO
production was determined indirectly as nitrite (NO2
-)
content in culture supernatants using the Griess Reagent
System (Promega).
Zymography
The potential proteolytic activity of MMPs in the superna-
tants of treated J774 cells was determined by zymography
as previously described [26]. The stained polyacrylamide
gels were observed with Image Quant RT ECL. Densitom-
etry of the bands corresponding to pro-MMP-9 activity
(92 kDa) was performed using NIH ImageJ program.
RNA analysis
RNA was extracted using the TRI Reagent (Applied Bio-
systems). RNA concentration was determined using
NanoVue (GE Healthcare). cDNA was synthesised using
the RevertAid kit (Fermentas).
Quantitative PCR (qPCR) primers were designed using
Primer3 software [27] (Table 1). qPCRs were performed
using the SYBR Green PCR Master Mix (Applied Biosys-
tems) on an ABI Prism 7500 instrument (Applied Bio-
systems). Sequence-specific amplification of cDNAs was
verified by melting-curve analyses. The threshold cycles
(Ct) were normalised to the mRNA expression of en-
dogenous GAPDH. Data analysis was performed using
the Q-Gene program (Equation 2) [28].
Statistical analysis
All statistical analyses were performed using Prism 5
(Graphpad Software). Either a one-way ANOVA with
Dunnett’s multiple comparison test (compared with the
CTR) or an independent samples t-test with unequal
variances (based on Levene’s test) assumption was used
to analyse the significance of differences. P-values less
than 0.05 were considered statistically significant.
Results
Soluble factors from breast cancer cells influence
macrophage activation
The secretion of several enzymes and cytokines was af-
fected upon macrophage culture with 3T3CM or 4T1CM.
The secretion profile was especially influenced by the
4T1CM followed by LPS stimulus (Figure 1 and Table 2).
The expression of the iNOS enzyme was increased upon
LPS stimulation of macrophages and was further up-
regulated upon incubation with 4T1CM followed by LPS
(Figure 1A). The increased expression of iNOS always
correlated with an increase in NO secretion (Figure 1C).
The expression and secretion of IL-6 and IL-12 by
macrophages was different if the cells were treated with
4T1CM alone or together with LPS (Figure 1A,B). 4T1CM
significantly decreased the mRNA expression of these
cytokines (IL-6, 0.7 and IL-12, 0.6-fold change, p = 0.006
and p = 0.007, respectively). Treatment with 4T1CM
followed by LPS yielded a 10-fold increase in the mRNA
expression of both IL-6 and IL-12 (p = 0.003 and p = 0.017,
respectively). Further, 4T1CM reduced IL-6 mRNA
expression upon LPS stimulation when compared with LPS
treatment alone (p = 0.041). The control 3T3CM induced
no such differences, suggesting cell line specificity of the
modulating factors (Figure 1A).
The secretion of IL-6 protein by macrophages reflected
the mRNA expression profile, except when the cells were
treated with 4T1CM followed by LPS; here, the decrease
observed at the mRNA level was not observed at the pro-
tein level (Figure 1A,B). Treatment with 3T3CM and
Table 1 List of primers used in the RNA analysis
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Figure 1 (See legend on next page.)
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4T1CM followed by LPS led to a significant increase in M-
CSF secretion when compared with unstimulated macro-
phages (p = 0.027 and p = 0.005, respectively). Furthermore,
incubation with 4T1CM, but not 3T3CM, significantly in-
creased the LPS-mediated M-CSF secretion by macro-
phages (p = 0.007).
Secretion of VEGF by macrophages was significantly in-
creased only upon 3T3CM treatment alone or followed by
LPS stimulation. In the latter conditions, VEGF secretion
was even higher than that induced by LPS treatment
alone. Incubation with 4T1CM together with LPS de-
creased VEGF production by macrophages when com-
pared with control-treated cells (Figure 1B).
Secretion of TNF-α and IL-10 was enhanced by treat-
ment with LPS (Figure 1B). This increase in IL-10 se-
cretion was significantly (p = 0.039) lower when the
macrophages were pre-treated with 4T1CM.
Incubation of macrophages with both 4T1CM and
LPS had similar agonistic but not additive effects on
MCP-1 secretion. Pre-treatment of macrophages with
3T3CM prior to LPS stimulation resulted in a 2.5-fold
increase in the mRNA expression of MMP-9 and
unique 1.5-fold increase in MMP-9 enzymatic activity
(Figure 1D). The level of secreted MCP-1 protein dir-
ectly correlated with the levels of secreted M-CSF and
TNF-α. IL-4 and IL-6 protein levels inversely correlated
with M-CSF and TNF-α levels (r = ±0.943 and p = 0.017,
respectively, Spearman nonparametric correlation).
Secretion profile of breast cancer cells and fibroblasts
4T1 and 3T3 cells had similar IL-6 and IL-12 mRNA
and protein levels (Figure 1E and F, respectively).
The amount of IL-10 secreted by 4T1 cells was low, but
higher than that produced by 3T3 cells (Figure 1F). Both
(See figure on previous page.)
Figure 1 Different mRNA and secreted cytokine profiles of 4T1 and 3T3 cells lead to differences in the modulation of J774 cell activation
status with or without LPS stimulus. A mRNA expression levels of iNOS, IL-6, IL-12, and MMP-9. B Protein levels of M-CSF, VEGF, TNF-α, IL-10, MCP-1
and IL-6 secreted by macrophages. C Nitrite (NO2
- ) production. Data represent the means ± SEM of 5 independent experiments. *p < 0.05, one-way
ANOVA with Dunnett’s multiple comparison test as compared with the CTR. D Zymography analysis of pro-MMP-9 in cell supernatants . Data represent
the means ± SEM of four independent experiments. *p < 0.05, **p < 0.005, student’s t-test as compared with the CTR or the CTR + LPS treatment (* lines
above the bars). E-G Data represent the means ± SEM of 3 independent 72-h post-confluence cultures assayed in duplicate. E Mean mRNA expression
levels of iNOS, IL-6, IL-12, and MMP-9 normalised to GAPDH. F Secreted protein levels of M-CSF, VEGF, TNF-α, IL-10, MCP-1 and IL-6. G Zymography
analysis of pro-MMP-9 in cell supernatants.
Table 2 Summary of results section “Soluble factors from breast cancer cells influence macrophage activation”
Cell lines 3T3 4T1 J774 Macrophages + CM
Markers 3T3 4T1 LPS 3T3 LPS 4T1 LPS
M1 iNOS/NO2
- +++/ND* +++/ND ≈CTR/≈CTR ≈CTR/≈CTR >CTR/>CTR ≈CTR/≈CTR >CTR/>CTR*
<LPS/≈LPS
TNF-α (protein) - ++ ≈CTR ≈CTR >CTR >CTR >CTR
≈LPS ≈LPS
IL-6 (mRNA /protein) +++/+++ +++/+++ ≈CTR/≈CTR <CTR/≈CTR >CTR/>CTR >CTR/>CTR
<LPS/≈LPS
IL-12 (mRNA /protein) ++/++ ++/++ ≈CTR/≈CTR <CTR/ND >CTR/ND >CTR/ND >CTR/ND
≈LPS/ND ≈LPS/ND
M2 MMP-9 (mRNA /protein) +++/++ +++/+++ ≈CTR/≈CTR ≈CTR/≈CTR ≈CTR/<CTR >CTR/≈CTR ≈CTR/≈CTR
≈LPS/>LPS ≈LPS/>LPS
VEGF (protein) +++ ++ >CTR ≈CTR ≈CTR >CTR <CTR
>LPS ≈LPS
IL-10 (protein) + ++ ≈CTR ≈CTR >CTR >CTR >CTR
≈LPS <LPS
M-CSF (protein) ++ +++ ≈CTR ≈CTR ≈CTR >CTR >CTR
≈LPS >LPS
MCP-1 (protein) ++ +++ ≈CTR >CTR >CTR >CTR >CTR
≈LPS ≈LPS
*ND, non detected; highlighted in bold are the significantly modulated markers either between the CM of 3T3 and 4T1 or compared to CTR or LPS macrophage
cultures.
+, ++, +++ abundance of mRNA or protein.
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cell lines secreted very low amounts of IL-4 (Figure 1F).
The presence of IL-4 and IL-12(p70) was detected but at
levels too low to reliably quantify.
4T1 and 3T3 cells secreted M-CSF (99.38 ± 8.94 pg/mL
and 11.95 ± 6.19 pg/mL) and MCP-1 (36.03 ± 6.29 pg/mL
and 6.20 ± 2.13 pg/mL), respectively (Figure 1F).3T3 cells
released considerable amounts of VEGF protein (638.47 ±
291.11 pg/mL), in contrast to 4T1 cells (Figure 1F). Only
4T1 cells secreted detectable, but low, amounts of TNF-α
(Figure 1F). The relative mRNA expression of iNOS and
MMP-9 was similar between the two cell lines. (Figure 1E).
MMP-9 proteolytic activity was higher in 4T1 than in 3T3
cells (Figure 1G).
Effect of free and liposome-encapsulated BPs on macrophages
ZOL was approximately 10-fold more potent than CLO
both in inhibiting growth and in inducing cell death in
J774 macrophages (Figure 2A). Liposome encapsulation
led to approximately 100-fold and 10-fold increase in
those capabilities of CLO and ZOL, respectively. As
demonstrated previously [29], treatment with CLO led
to the accumulation of the ATP analogue, 5′(β,γ-dichlor-
omethylene)triphosphate (AppCCl2p) (Figure 2B). Like
the free drug [17], ZOL-LIP inhibited FDPS, resulting in
the accumulation of IPP, ApppI and unprenylated Rap1A
(uRap1A) (Figure 2B,C).
CLO and ZOL have different effects on the activation
status of 4T1CM-primed macrophages
ZOL-LIP treatment induced a significant (2-fold) in-
crease in iNOS expression (Figure 3A), but not in NO
secretion by J774 cells (Figure 3C). Treatment with CLO
and CLO-LIP resulted in a significant decrease in NO
production (Figure 3C), but this was not observed at the
mRNA level (Figure 3A).
CLO, CLO-LIP and ZOL-LIP treatments significantly
decreased the mRNA expression of IL-6 and IL-12 in J774
cells (Figure 3A). IL-6 protein levels were also significantly
decreased upon CLO and CLO-LIP treatment (p = 0.006
and p = 0.005, respectively) (Figure 3B). At the mRNA
level, treatment with both CLO and CLO-LIP increased
MMP-9 expression in J774 macrophages (Figure 3A).
However, the mRNA data were not reflected in the en-
zymatic activity as determined by zymography (Figure 3D).
Only the ZOL-LIP treatment induced an over 10-fold in-
crease in MMP-9 mRNA expression and a 2-fold increase
in enzymatic activity (Figure 3A,D).
Incubation with CLO and CLO-LIP decreased M-CSF se-
cretion by macrophages (p = 0.016), whereas incubation
with ZOL and ZOL-LIP had no effect (Figure 3B). All the
liposomal treatments, even empty liposomes (EMP-LIP),
decreased the protein secretion of IL-10, suggesting an ef-
fect of the liposomal formulation per se rather than a BPs’
Figure 2 Comparison of free and liposome encapsulated CLO and ZOL potencies. A Effect of BPs on the growth inhibition and cytotoxicity
of J774 cells after 48 h of treatment. IC50 and EC50 values represent the 95% confidence intervals of the normalised, non-linear fitted values. B IPP,
ApppI and AppCCl2p accumulation in J774 cells after BP treatment. ND, levels below the limit of detection. ***p < 0.0001, one-way ANOVA
with Dunnett’s multiple comparison test as compared with the CTR. C Western blot analysis of the effect of ZOL, ZOL-LIP and EMP-LIP treatment on
protein prenylation and other key mevalonate pathway molecules. The results are representative of three independent experiments.
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effect (Figure 3B). ZOL-LIP was the only treatment that
significantly increased TNF-α secretion by macrophages
when compared to untreated or EMP-LIP treated cells (p =
0.017 and 0.021, respectively; Figure 3B). 4T1CM together
with LPS stimulation did not significantly affect the BP in-
duced accumulation of AppCCl2p, IPP or ApppI in macro-
phages (Figure 3E), indicating that the mechanisms of BPs
action were not affected [13].
Secreted MCP-1 protein levels correlated with M-CSF
protein levels (r = 0.943, p = 0.017), and IL-6 protein levels
inversely correlated with VEGF protein levels (r = -0.886,
p = 0.03) (Spearman nonparametric correlation). In all the
conditions tested (Figures 1C and 3B), IFN-γ levels were
below the limit of detection.
Discussion
Incubation of J774 macrophages with 4T1CM reduced the
mRNA expression of IL-6 and IL-12 and made them less
responsive to LPS. These findings suggested that 4T1CM
diminished the capability of macrophages to mount a pro-
inflammatory response. However, there appeared to be a
delay between the transcriptional and secretory IL-6 re-
sponses. In the multiplex ELISA we analyse only the se-
creted cytokines in the macrophage culture supernatants
and not total levels, the mismatched mRNA and protein
levels may therefore be a combination of miRNA transla-
tional block of IL-6 mRNA or a decreased secretion of the
produced protein, especially as the expected result was a
decrease from rather high IL-6 secretion induced by the
LPS stimulus. Cytokines in the supernatants and mRNAs
were analysed at the same time point, in matched samples
(i.e. supernatant was collected from the same well used for
RNA extraction).
4T1CM treatment counteracted the LPS-induced de-
crease in MMP-9 activity, suggesting that 4T1CM in-
creased MMP-9 expression and that the activity of
MMP-9 was not fully suppressed by LPS. The soluble
factors secreted by 4T1 cells appeared to reduce the
Figure 3 Effect of BPs on the response to LPS in 4T1CM-treated J774 cells. A mRNA expression of iNOS, IL-6, IL-12, and MMP-9. B Protein
levels of M-CSF, VEGF, TNF-α, IL-10, MCP-1 and IL-6 secreted by macrophages. *p < 0.05, **p < 0.005, student’s t-test as compared with the CTR
and EMP-LIP (* lines above the bars). C Nitrite (NO2
- ) production. *p < 0.05, one-way ANOVA with Dunnett’s multiple comparison test as compared
with the CTR. A-C Data represent the means ± SEM of 4 independent experiments. D Zymography analysis of pro-MMP-9 in J774 cell supernatants.
Presented values are the optical densities of pro-MMP-9-digested bands normalised to the total protein content of the corresponding total cell lysate
compared with appropriate controls (CTR or EMP-LIP). E IPP, ApppI and AppCCl2p levels after treatment. Data represent the means ± SEM of three
independent experiments. ***p < 0.0001, one-way ANOVA with Dunnett’s multiple comparison test as compared with the CTR.
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production of inflammatory cytokines and favour the ex-
pression of MMP-9. The cytokine expression profile of
the 4T1CM-treated macrophages was mostly characteris-
tic of M2-type cells. However, there was still an increased
iNOS expression and NO production, markers typical of
an M1 phenotype [30]. Nevertheless, several studies have
indicated a dual time and concentration dependent role
for iNOS expression in breast cancer progression. Mice
lacking iNOS experience longer periods of latency in
mammary tumour growth. In contrast, high NO produc-
tion promotes the cytotoxicity of TAMs against breast
cancer cells, and low NO concentration promotes angio-
genesis and cancer cell invasion. In a co-culture study
breast cancer cells induced NO production by macro-
phages, which promoted cancer cell invasion favouring
VEGF-A and MMP-9 expression [31,32].
Treatment with both 3T3CM and 4T1CM sensitised
macrophages to LPS in terms of M-CSF production. The
two cell lines produced significant amounts of M-CSF, es-
pecially 4T1. The higher M-CSF protein levels observed in
the supernatants of macrophages treated with 4T1CM
and LPS might be the sum of macrophage- and 4T1 cell-
derived M-CSF. In the context of breast cancer metastasis
to bone, it is known that the M-CSF produced by human
breast cancer cell lines increases osteoclast survival and
activity [33], stimulates macrophage expansion, and up-
regulates receptor activator of nuclear factor kappa-B
ligand (RANKL) expression in stromal cells [34]. Further-
more, binding of breast cancer cell-derived M-CSF pro-
motes epithelial growth factor (EGF) production by
macrophages. This process leads to the reciprocal activa-
tion of invasion and co-migration of both cell types [35].
These observations were supported by our results. M-CSF
was secreted by macrophages incubated in 4T1CM, and
the secretion was boosted with LPS simulus.
MCP-1 was produced by 3T3 cells and at higher levels
by 4T1 cells. A positive feedback loop has been demon-
strated in mouse mammary tumours whereby the cancer
cells release MCP-1; this promotes macrophage secre-
tion of TNF-α, which in turn promotes further MCP-1
expression by cancer cells [36]. A similar loop was ob-
served in the present study, as 4T1CM pre-treated mac-
rophages demonstrated an elevated secretion of both
MCP-1 and TNF-α.
4T1CM alone did not affect TNF-α secretion by mac-
rophages, but the media had an agonistic effect on the
cells when LPS was introduced. Similar results have been
demonstrated in a human co-culture study in which
cancer cells increased TNF-α expression in macro-
phages, thus inducing MMP expression and activity [37].
In the present study, both fibroblast- and breast cancer-
CM showed similar effects on macrophages, as both in-
duced higher secretion levels of TNF-α and higher
MMP-9 activity in LPS stimulated macrophages.
Cancer cells produce small amounts of VEGF, a protein
that could auto-stimulate neoangiogenesis and tumour
growth. However, fibroblasts and macrophages produce
considerably larger amounts of VEGF being in that sense
more significant supporters of tumour growth rather than
the cancer cells alone [38]. In a co-culture model, breast
cancer cell secreted factors increased VEGF production by
macrophages [38]. In our study, 3T3CM was the strongest
stimulus inducing VEGF secretion by macrophages, a re-
sult emphasising the relevance of fibroblast-secreted fac-
tors in cancer progression. The VEGF levels may be
attributed to both macrophage and 3T3 cell production.
Release of IL-10 is a well-described monocyte response
to LPS. However, in human PBMCs, IL-10 pre-treatment
has been shown to desensitise the cells to LPS in terms
of IL-10 and TNF-α production [39]. The same
phenomenon may explain the diminished IL-10 re-
sponse observed in the LPS stimulated macrophages
pre-treated with 4T1CM, as 4T1 cells secreted more
IL-10 than 3T3 cells.
As previously demonstrated, treatment with both
CLO and CLO-LIP decreased the NO, IL-6, and IL-12
mRNA and protein expression in macrophages [40],
and for the first time, we showed decreased M-CSF
mRNA and protein production by CLO and CLO-LIP
treated macrophages. The effect of CLO alone was a
real transcriptional effect, as cell viability was not af-
fected (results not shown). CLO-LIP treatment reduced
cell viability. Thus, its effect may be partially attributed to
cytotoxicity. Similarly to reports using other N-BPs, ZOL
treatment did not have an effect on macrophage NO pro-
duction [41,42]. IL-6, IL-12, cytokines related to the acute
phase reaction, are known to be up-regulated by low-dose
N-BPs both in vivo and in vitro [40,41,43,44]. In studies
with alendronate, the acute phase cytokine profile has
been shown to be unrelated to FDPS inhibition [44]. How-
ever, no previous in vitro data exist for the effects of ZOL
or ZOL-LIP in this context. Our results further confirmed
that N-BPs interfere with macrophage cytokine produc-
tion, but the mechanism of action of this effect is still un-
known. ZOL treatment appeared to increase the mRNA
expression of IL-6 and IL-12, but this increase was not de-
tected at the protein level. ZOL-LIP treatment decreased
IL-6 mRNA similarly as previously reported for liposome-
encapsulated pamidronate (an N-BP) and CLO-LIP [40].
The increase in TNF-α production observed upon ex-
posure of macrophages to ZOL-LIP is consistent with
the effect of pamidronate [45], which induced TNF-α
production by mouse macrophages. In the same study, it
was shown that CLO suppressed IFN-γ-induced TNF-α
production [45]. The N-BP-induced increase in TNF-α
production has been observed also in cultured human
PBMCs treated with pamidronate [46]. We have previ-
ously shown the opposite effects of N-BPs and non-N-
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BPs on TNF-α production by macrophages [47]. In the
current study, CLO and CLO-LIP treatments did not
significantly decrease TNF-α secretion by macrophages,
whereas a significant increase was observed upon expos-
ure to ZOL-LIP. Activation of TNF-α production by N-
BPs may be beneficial, as certain malignant tumours are
sensitive to this cytokine [48].
The apparent discrepancies between MMP-9 mRNA ex-
pression and its potential activity levels are consistent with
a previous study on the effects of BPs on MMPs [49]. Fur-
ther, it has been demonstrated that CLO inhibits the en-
zymatic activity of purified MMP-9 protein, whereas ZOL
demonstrates no such inhibition [50]. In our study, both
CLO and CLO-LIP treatments enhanced the mRNA ex-
pression of MMP-9, whereas only ZOL-LIP treatment in-
creased both MMP-9 expression and activity. Our results
with ZOL-LIP treatment confirmed previous findings
where ZOL did not inhibit MMP-9 activity [50]. The ZOL
doses used in the current study are comparable to the low
pamidronate doses used by others [49]. The increased
MMP-9 expression therefore appears to be a typical re-
sponse to low-dose N-BP treatments. Higher doses of N-
BPs inhibit protein prenylation, thereby impairing several
cellular functions, and they most likely also diminish
MMP enzyme production or secretion. Recently, exogen-
ous gene transfer of MMP-9 was shown to suppress
tumours by increasing neutrophil infiltration into the
tumour site, a process that enhances macrophage secre-
tion of pro-inflammatory cytokines and decreases IL-10
production [51]. In light of this, enhanced MMP-9 expres-
sion by macrophages upon exposure to ZOL-LIP may be
beneficial in the tumour microenvironment.
Conclusions
To our knowledge, the above effects have never been
shown in murine macrophage cell lines conditioned ex-
clusively with soluble factors secreted by murine breast
cancer cells. The findings are in line with those from
similar studies performed with freshly isolated human
monocytes and conditioned media from melanoma cells
[3]. Additionally, the current findings are of particular
relevance because the cross talk between human macro-
phages and breast tumour cells is essential for the first
steps in metastasis formation [52].
Our results suggest that the effects of non-N-BPs and
N-BPs on macrophage activation are distinct, when used
in sub-lethal doses. If the objective is to reduce inflam-
mation or to eradicate macrophages, a non-N-BP may
be used, as we saw that CLO and CLO-LIP were cyto-
toxic to macrophages and decreased most of the M1
markers tested. If the aim is to alter macrophage activa-
tion without decreasing inflammation, an N-BP may be
more adequate, as it was seen that in the doses used
ZOL-LIP presented few cytotoxic effects and maintained
(NO2
- , IL-6, IL-12) or increased(iNOS and TNF-α) M1
markers after LPS activation.
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